Alpha Teknova Inc (TKNO) Peer Comparison

$7.31

$0.09 (1.25%)

As on 27-Aug-2026 16:00EDT

Market cap

$395 Mln

Revenue (TTM)

$44 Mln

P/E Ratio

--

P/B Ratio

6

Div. Yield

0 %

Edit

	Alpha Teknova Inc (TKNO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Market cap ($ Mln)	395	12,753	10,906	9,762	10,222
Revenue ($ Mln)	44	1,505	613	2,589	785
Net Profit ($ Mln)	-16.77	160.59	-188.05	222.40	41.54
Net Margin (%)	-38.37	10.67	-30.68	8.59	5.29
RoE (%)	-25.53	10.86	-28.10	3.04	1.97
Price to Earnings	--	79.35	--	44.47	251.57
Price-To-Book	6.00	8.41	16.38	1.26	4.84

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Alpha Teknova Inc (TKNO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Operating Revenue	43.70	1,504.87	612.84	2,589.30	785.10
Cost of Revenue	28.87	483.98	127.96	1,245.50	384.30
Gross Profit	13.44	942.44	393.22	1,343.60	347.62
Operating Expenses	30.65	833.56	565.37	1,108.90	335.50
Operating Profit (EBIT)	-15.81	187.34	-80.49	235.00	65.30
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-16.68	203.83	-192.83	350.40	52.15
Provision for Tax	0.09	43.24	-4.79	128.00	10.61
Profit after Tax (Net Income)	-16.77	160.59	-188.05	222.40	41.54
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	Alpha Teknova Inc (TKNO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Shareholder's Funds	62.60	1,530.77	682.49	7,173.90	2,112.03
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	26.41	210.18	135.71	2,116.80	705.49
Current Liabilities	6.87	233.78	102.33	961.30	132.66
Total Liabilities	103.58	1,826.52	893.49	10,576.50	2,949.70

Assets ($ Mln)

	Alpha Teknova Inc (TKNO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Non-Current Assets	65.05	630.60	404.74	7,231.50	1,749.63
Current Assets	30.82	1,344.12	515.78	3,020.50	1,200.55
Total Assets	103.58	1,826.52	893.49	10,576.50	2,949.70
Total Debt*	27.41	212.71	102.84	1,203.70	690.94
Net Current Assets	23.95	1,110.35	413.45	2,059.20	1,067.90

Cashflow ($ Mln)

	Alpha Teknova Inc (TKNO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Cash From Operating Activities	-8.65	238.66	-46.34	532.20	117.42
Cash Flow from Investing Activities	10.70	-404.59	-77.61	-189.70	-298.47
Cash from Financing Activities	0.15	26.53	11.89	-283.20	-15.21
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Alpha Teknova Inc (TKNO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
ROCE (%)	-17.57	11.76	-22.53	8.98	1.79
ROE (%)	-25.53	10.86	-28.10	3.04	1.97
ROA (%)	-15.26	7.95	-18.00	2.02	1.36
EBIT Margin (%)	-36.16	13.63	-30.58	-5.99	9.87
Net Margin (%)	-38.37	10.67	-30.68	8.59	5.29
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Alpha Teknova Inc (TKNO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Revenue Growth (%)	12.27	17.55	41.55	1.37	16.49
EBIT Growth (%)	24.48	17.49	-116.42	-131.06	920.91
Net Profit Growth (%)	22.00	8.72	-102.66	-30.32	400.42
EPS Growth (%)	27.34	8.12	-96.88	-29.66	394.30
Book Value Growth (%)	-17.98	17.33	-12.65	2.19	2.16

Valuation Ratios

	Alpha Teknova Inc (TKNO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Price / Earnings	-11.79	68.93	-34.59	--	189.42
Price / Book Value	2.96	8.58	9.90	--	4.40
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-19.44	53.25	-43.50	--	55.90
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Alpha Teknova Inc (TKNO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debt to Equity	0.21	0.00	0.00	0.11	0.26
Short term debt to equity ratio	0.03	0.01	0.00	0.06	0.01
Current Ratio	4.49	5.75	5.04	3.14	9.05
Quick Ratio	3.48	3.86	4.46	2.33	7.64
Interest Coverage	-18.12	157.91	-38.31	8.18	3.36

Operating Efficiency Ratios

	Alpha Teknova Inc (TKNO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debtors to sales (%)	12.38	12.65	22.67	17.06	20.09
Asset Turnover	0.40	0.74	0.59	0.24	0.26
Receivable days	40.25	46.54	60.95	65.39	72.41
Inventory Days	93.44	331.92	193.84	221.09	146.53
Payable days	14.86	26.16	60.19	37.02	29.05
Cash Conversion Cycle	118.83	352.30	194.60	249.46	189.88

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly